Bullous Pemphigoid (BP) Terminated Phase 2 Trials for Ligelizumab (DB11856)

Also known as: Pemphigoid, Bullous / Bullous Pemphigoid / Pemphigoid / Bullous pemphigoid NOS

IndicationStatusPhase
DBCOND0074370 (Bullous Pemphigoid (BP))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01688882Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid TreatmentTreatment